108 related articles for article (PubMed ID: 29940824)
1. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
2. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
Latimer NR; White IR; Tilling K; Siebert U
Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
[TBL] [Abstract][Full Text] [Related]
3. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
Latimer NR; Dewdney A; Campioni M
BMC Med Res Methodol; 2024 Jan; 24(1):17. PubMed ID: 38253996
[TBL] [Abstract][Full Text] [Related]
4. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
5. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).
Lengliné E; Baba J; de Boissieu P; Beaufils A; Desbiolles A; Diatta T; Cochat P; Chevret S
Eur J Cancer; 2024 Jun; 204():114047. PubMed ID: 38653034
[TBL] [Abstract][Full Text] [Related]
6. Equal censoring but still informative: When the reasons for censoring differ between treatment arms.
Olivier T; Prasad V
Eur J Cancer; 2024 Apr; 201():113942. PubMed ID: 38382151
[TBL] [Abstract][Full Text] [Related]
7. Non-inferiority trials with time-to-event data: clarifying the impact of censoring.
Choi J; Xue X; Kim M
J Biopharm Stat; 2024 Mar; 34(2):222-239. PubMed ID: 37042702
[TBL] [Abstract][Full Text] [Related]
8. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
Lesan V; Olivier T; Prasad V
Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
[TBL] [Abstract][Full Text] [Related]
9. Randomization inference with general interference and censoring.
Loh WW; Hudgens MG; Clemens JD; Ali M; Emch ME
Biometrics; 2020 Mar; 76(1):235-245. PubMed ID: 31388990
[TBL] [Abstract][Full Text] [Related]
10. Comparison of baseline covariate adjustment methods for restricted mean survival time.
Hanada K; Moriya J; Kojima M
Contemp Clin Trials; 2024 Mar; 138():107440. PubMed ID: 38228232
[TBL] [Abstract][Full Text] [Related]
11. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Apr; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
12. A nonparametric relative treatment effect for direct comparisons of censored paired survival outcomes.
Dobler D; Möllenhoff K
Stat Med; 2024 May; 43(11):2216-2238. PubMed ID: 38545940
[TBL] [Abstract][Full Text] [Related]
13. A causal framework for classical statistical estimands in failure-time settings with competing events.
Young JG; Stensrud MJ; Tchetgen Tchetgen EJ; Hernán MA
Stat Med; 2020 Apr; 39(8):1199-1236. PubMed ID: 31985089
[TBL] [Abstract][Full Text] [Related]
14. Mediation Analysis for Censored Survival Data Under an Accelerated Failure Time Model.
Fulcher IR; Tchetgen Tchetgen EJ; Williams PL
Epidemiology; 2017 Sep; 28(5):660-666. PubMed ID: 28574921
[TBL] [Abstract][Full Text] [Related]
15. Distorted correlations among censored data: causes, effects, and correction.
Barchard KA; Russell JA
Behav Res Methods; 2024 Mar; 56(3):1207-1228. PubMed ID: 38129736
[TBL] [Abstract][Full Text] [Related]
16. Improved 30-Day Survival Estimation in ICU Patients: A Comparative Analysis of Different Approaches With Real-World Data.
Vacheron CH; Friggeri A; Gerbaud-Coulas C; Dagonneau T; Timsit JF; Allaouchiche B; Wallet F; Bohe J; Piriou V; Maucort-Boulch D; Fauvernier M
Crit Care Med; 2024 Mar; 52(3):432-440. PubMed ID: 37882642
[TBL] [Abstract][Full Text] [Related]
17. Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters.
Jennings AC; Rutherford MJ; Latimer NR; Sweeting MJ; Lambert PC
Value Health; 2024 Mar; 27(3):347-355. PubMed ID: 38154594
[TBL] [Abstract][Full Text] [Related]
18. Constructing dynamic treatment regimes with shared parameters for censored data.
Zhao YQ; Zhu R; Chen G; Zheng Y
Stat Med; 2020 Apr; 39(9):1250-1263. PubMed ID: 31951041
[TBL] [Abstract][Full Text] [Related]
19. Deep learning for survival outcomes.
Steingrimsson JA; Morrison S
Stat Med; 2020 Jul; 39(17):2339-2349. PubMed ID: 32281672
[TBL] [Abstract][Full Text] [Related]
20. Impact of the Management and Proportion of Lost to Follow-Up Cases on Cancer Survival Estimates for Small Population-Based Cancer Registries.
Gil F; Miranda-Filho A; Uribe-Perez C; Arias-Ortiz NE; Yépez-Chamorro MC; Bravo LM; de Vries E
J Cancer Epidemiol; 2022; 2022():9068214. PubMed ID: 35140789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
